^
    Back
    Association details:
    Biomarker:ER negative
    Cancer:HER2 Positive Breast Cancer
    Regimen: (docetaxel + Perjeta (pertuzumab) + Herceptin (trastuzumab) + carboplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland

    Published date:
    02/26/2022
    Excerpt:
    In a univariate analysis, the odds of achieving pCR were 14 times higher in the ER-negative arm compared with the ER-positive group (p = 0.004). This was confirmed by the multivariate analysis: ER status (OR: 0.01, 95% CI: 0.00–0.16; p = 0.005)....Our study confirmed that the TCbH-P regimen is safe and relatively effective in the neoadjuvant treatment of patients with HER2-positive breast cancer.
    DOI:
    10.3390/cancers14051218
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    The impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience

    Published date:
    10/01/2018
    Excerpt:
    The highest pCR rate was seen amongst ER negative patients receiving D (81%)…All 9 ER negative patients treated with TCHP achieved pCR (100%) compared with FEC-THP (67%).
    DOI:
    https://doi.org/10.1093/annonc/mdy270.218